ConductScience.org, home

Comparison · NCT03065244-6d6ed673

IVIG vs Infliximab: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. IVIG vs Infliximab: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. Trial comparisons, record NCT03065244-6d6ed673. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03065244-6d6ed673

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.510.3750.644wilson
Risk in group 20.7690.6390.863wilson
Risk difference, group 1 minus group 2-0.259-0.424-0.0719newcombe hybrid score
Risk ratio, group 1 over group 20.6630.4850.906log
Odds ratio, group 1 over group 20.3130.1330.734log
Number needed to treat, for one fewer participant with the outcome on IVIG than on Infliximab3.862.3613.9from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1IVIGPatient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion~IVIG: Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours2549OG000
Group 2InfliximabPatient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours~Infliximab: Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours4052OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days.
Description
A fever will be considered ≥38°C rectally or orally and ≥ 37.5°C axillary. Cessation of fever within 24h of initiation of study treatment with no fever recurrence within next 7 days.
Time frame
7 days
Population

Source ClinicalTrials.gov

Trial

Title
KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
NCT number
NCT03065244
Phases
PHASE3
Conditions
Mucocutaneous Lymph Node Syndrome
Interventions
IVIG, Infliximab
Lead sponsor
University of California, San Diego
Results first posted
2021-12-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03065244-6d6ed673